These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia]. Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363 [TBL] [Abstract][Full Text] [Related]
5. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400 [TBL] [Abstract][Full Text] [Related]
6. [Dynamically monitoring minimal residual disease in acute leukemia after complete remission by multiparameter flow cytometry and its relation with prognosis]. Sun NN; Gan SL; Sun H; Zhang QT; Liu YF; Xie XS Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):339-42. PubMed ID: 23628028 [TBL] [Abstract][Full Text] [Related]
7. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion. Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019 [TBL] [Abstract][Full Text] [Related]
8. Minimal/Measurable Residual Disease Monitoring in Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199 [TBL] [Abstract][Full Text] [Related]
9. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155 [TBL] [Abstract][Full Text] [Related]
10. Should minimal residual disease guide therapy in AML? Paietta E Best Pract Res Clin Haematol; 2015; 28(2-3):98-105. PubMed ID: 26590765 [TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease in acute myeloid leukemia: coming of age. Paietta E Hematology Am Soc Hematol Educ Program; 2012; 2012():35-42. PubMed ID: 23233558 [TBL] [Abstract][Full Text] [Related]
16. A mind map for managing minimal residual disease in acute myeloid leukemia. Benton CB; Ravandi F Clin Adv Hematol Oncol; 2017 Nov; 15(11):859-867. PubMed ID: 29200419 [TBL] [Abstract][Full Text] [Related]
17. Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia. Yu T; Chi J; Wang L Hematology; 2021 Dec; 26(1):848-859. PubMed ID: 34674615 [TBL] [Abstract][Full Text] [Related]
18. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets. Rossi G; Minervini MM; Carella AM; de Waure C; di Nardo F; Melillo L; D'Arena G; Zini G; Cascavilla N Leuk Res; 2012 Apr; 36(4):401-6. PubMed ID: 22196957 [TBL] [Abstract][Full Text] [Related]
19. Can Minimal Residual Disease Determination in Acute Myeloid Leukemia Be Used in Clinical Practice? Luskin MR; Stone RM J Oncol Pract; 2017 Aug; 13(8):471-480. PubMed ID: 28796964 [TBL] [Abstract][Full Text] [Related]
20. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease. Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]